Cethrin
Navigation Links
Cethrin in Medical News
Alseres Shares Begin Trading on the Pink Sheets OTC Market
...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice - 508-497-2360 ext. 226 Alseres Pharmaceu...Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
...ed in December 2006 and amended in March 2007 (the cethrin License) was further amended. The Amendment repla...nd performance-related milestones contained in the cethrin License with a formula-based approach to sharing a...nt for the compounds and technology covered by the cethrin License. In the event that the Company fails to s......iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice - 508-497-2360 ext. 226 Alseres Pharmaceu...
Alseres Pharmaceuticals, Inc. Announces $200,000 Financing
...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice -- 508-497-2360 ext. 226 Alseres Pharma...Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements
...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia Alseres Pharmaceuticals, Inc 50...Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
...ing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext. 224 Alseres Pha...Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call
...providing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals,...Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
...yndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals...Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
...ful, this trial will provide us with evidence that cethrin is more effective than a placebo in treating acute...ur preliminary planning for the Phase IIb trial of cethrin called for us to enroll up to 100 subjects in 80 s...ropriate sites and investigators for the Phase IIb cethrin study expected to commence in the first quarter of...Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
...providing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals...Cethrin in Medical Technology
Company Announces Extension of Phase I/IIa Trial to 9 mg Dosage
Level
HOPKINTON, Mass., April 16, 2007 /PRNewswire-FirstCall/ --
Boston Life Sciences announced today that clinical data on its lead
nerve repair therapy, Cethrin(R), were presented in the Neurotrauma
and Critical Care Scientific Sess...
...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres ...
... Analysis of the data by dose group indicates that cethrin doses of 1 and 3 mg appear to be the most benefici... ) "The safety and efficacy observations of the cethrin trial continue to be encouraging. Many patients ha...orward with its previously announced plans for the cethrin Phase IIb trial in acute spinal cord injury in the...
...eres may exercise an option to amend the Company's cethrin License Agreement. (Logo: http://www.newscom.co...ard for Alseres in realizing the full value of our cethrin spinal cord program and our Rho inhibitor technolo...cts in a Phase I/IIa clinical trial indicated that cethrin was safe and well tolerated. The overall populatio...
...rmation in this press release as of this date and assumes no obligations to update the information in this press release. Alseres is a trademark and cethrin and ALTROPANE are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext 224 scorreia@alseres.com or ...
...ark Hurtt, Chief Medical Officer, will discuss the cethrin development program as a member of an expert panel...ion, Dr. Hurtt will present interim results of the cethrin Phase I/IIa clinical trial in acute spinal cord in...acy results from the first 37 patients in Alseres' cethrin Phase I/IIa study. The data indicated that...
...ed enrollment in the Phase I/IIa clinical trial of cethrin in acute spinal cord injury (SCI). A total of 48 s...iously announced plans for the placebo-controlled, cethrin Phase IIb trial in acute spinal cord injury at sit...rope and other countries in 2008. "We believe that cethrin continues to be the most advanced drug candidate i...
... DSMB's recommendation is an important step in the cethrin clinical plan," commented Dr. Mark Hurtt, Alseres'...understanding of the encouraging efficacy data for cethrin at lower doses, and provide additional safety data...ient enrollment in early 2008." About Cethrin(R) cethrin is a recombinant protein drug intended to facilita...
...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres ...
... Analysis of the data by dose group indicates that cethrin doses of 1 and 3 mg appear to be the most benefici... ) "The safety and efficacy observations of the cethrin trial continue to be encouraging. Many patients ha...orward with its previously announced plans for the cethrin Phase IIb trial in acute spinal cord injury in the...
...eres may exercise an option to amend the Company's cethrin License Agreement. (Logo: http://www.newscom.co...ard for Alseres in realizing the full value of our cethrin spinal cord program and our Rho inhibitor technolo...cts in a Phase I/IIa clinical trial indicated that cethrin was safe and well tolerated. The overall populatio...
...rmation in this press release as of this date and assumes no obligations to update the information in this press release. Alseres is a trademark and cethrin and ALTROPANE are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext 224 scorreia@alseres.com or ...
...ark Hurtt, Chief Medical Officer, will discuss the cethrin development program as a member of an expert panel...ion, Dr. Hurtt will present interim results of the cethrin Phase I/IIa clinical trial in acute spinal cord in...acy results from the first 37 patients in Alseres' cethrin Phase I/IIa study. The data indicated that...
...ed enrollment in the Phase I/IIa clinical trial of cethrin in acute spinal cord injury (SCI). A total of 48 s...iously announced plans for the placebo-controlled, cethrin Phase IIb trial in acute spinal cord injury at sit...rope and other countries in 2008. "We believe that cethrin continues to be the most advanced drug candidate i...
... DSMB's recommendation is an important step in the cethrin clinical plan," commented Dr. Mark Hurtt, Alseres'...understanding of the encouraging efficacy data for cethrin at lower doses, and provide additional safety data...ient enrollment in early 2008." About Cethrin(R) cethrin is a recombinant protein drug intended to facilita...
Cethrin in Biological Technology
Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. http://www.alseres.com/ Contact: Kenneth L. Rice 508...Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice -- 508-497-2360 ext. 226 Alseres Pharma...Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
...8, in Washington, DC by Dr. Michael Fehlings, principal Investigator of the cethrin Phase I/IIa trial. -- We are pursuing development and commercialization p... no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. ...Alseres Pharmaceuticals, Inc. Raises $5 Million
...rmation in this press release as of this date and assumes no obligations to update the information in this press release. Alseres is a trademark and cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext. 224 Alseres Pharmaceut...Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
...d Injury on the first 37 subjects treated with cethrin at doses up to 6 mg. The data indicated that cethrin was safe and well tolerated. The overall population of patients treated with cethrin demonstrated an improvement in their impairmen......tegies, plans or prospects regarding the future, including the Company's clinical development and trials for CETHRIN, the prospects of FDA approval of cethrin and the commercialization, including partnering opportunities, of CETHRIN. Forward- looking statements can be identified by terminology such as "antic...
Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference
...cted in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the t...Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
...cted in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the t...Other TagsmythAURAappearappearSocietySocietyraysraysraysraysraysYesYesYesYesYescommunicationsOther Contentsprokaryotesprokaryotesprokaryotesprokaryotesproofproofproofproofproofproofprostaglandinsprostaglandinsprostateprostateprostateprostateprostateprostateprostatearrayarrayarrayarrayarrayarrayarrayarrayfoldingfoldingfoldingfoldingfoldingfolding
substantiallymythmarulapeersAURAdiffersappearSocietyspotlightedraysYestrickerybioconjugatescommunications
(Date:12/14/2009)... now provides in-home caregivers who have been certified by the ... therapy, caregiver, and hospice services to San Francisco Bay Area ... ... (PRWEB) December 14, 2009 -- Professional HealthCare at Home, the ... care, including nursing, rehab, personal caregiver and hospice services, has ...
(Date:12/14/2009)... 14 Josie Raper, a 29 year-old mother from ... months with the help of the Dr. Siegal,s COOKIE DIET® ... Joy Fit Club segment on NBC,s Today Show. The Joy ... airs twice a month and salutes those who have lost ... and has kept it off for two years. ,, "The ...
(Date:12/14/2009)... Only about one in 2,000 people in the United ... of the unfortunate few. , Ms. Wilcox,s tumor was a ... those problems were mistaken for blocked sinuses. , "For several ... my nose," recalled the resident of Goldthwaite, a town of ... "I felt a fullness, but I didn,t take that as ...
(Date:12/14/2009)... the December issue of Mayo Clinic Proceedings , ... This retrospective study is the largest ever conducted in ... a serious disorder that disrupts the body,s normal production ... the bone marrow, leading to severe anemia, weakness, fatigue ... "In the past 20 years, management of primary myelofibrosis ...
(Date:12/14/2009)... long-term solution, researchers say , , MONDAY, Dec. 14 ... dislocations can benefit from a procedure that "sculpts" ... cadavers, new research suggests. , The study, ... American Journal of Sports Medicine , finds that ... that stabilize or reconstruct a shoulder joint by ...
Breaking Medicine News(10 mins):Health News:Caregivers with Professional HealthCare at Home Now Certified by the Alzheimer's Association 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 3Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 4Health News:Minimally invasive surgery removes sinus tumor without facial disfiguration 2[0] Caregivers with Professional HealthCare at Home Now Certified by the Alzheimer's Association [0] Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club[0] Minimally invasive surgery removes sinus tumor without facial disfiguration[0] Mayo Clinic Proceedings: Researchers find evidence of survival gains in bone marrow disease[0] Shoulder Repair Technique Borrows From Cadavers
(Date:12/11/2009)... the 4th edition of Springer,s classic reference and textbook ... Victor A. McKusick Leadership Award. The prize, which recognizes ... genetics, was presented to him at the 59th Annual ... 24 October 2009 in Honolulu, Hawaii. , Motulsky is ... University of Washington in Seattle. One of the founding ...
(Date:12/11/2009)... CORVALIS, ORFruit growers, profits have traditionally been ... climates where growing seasons can be short. ... developed varieties are being introduced that offer ... the offseasonresulting in economic bonuses for both ... new varieties of blackberry called "primocane-fruiting", which ...
(Date:12/11/2009)... health risk but why do teens become addicted to ... Faculty of 1000 Biology, Neil Grunberg looks into why ... describes the study, published by Natividad et al. in ... "may have implications to help understand why adolescents are ... level of dopamine in the brain, a neurotransmitter that ...
Breaking Biology News(10 mins):New management methods extend blackberry season 2Clemson researchers say algae key to mass extinctionss 10451 1Clemson researchers say algae key to mass extinctionss 10451 2Smallest nanoantennas for high speed data networks 14552 1Smallest nanoantennas for high speed data networks 14552 2Smallest nanoantennas for high speed data networks 14552 3In Case You Missed It 3A Landrieu Discusses Health Care Reform on MSNBC 59868 1| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |